BALTIMORE--(BUSINESS WIRE)--June 5, 2006--Acusphere, Inc (Nasdaq: ACUS - News) today announced the completion of enrollment in the second of its two Phase 3 clinical trials, RAMP-2 (Real-time Assessment of Myocardial Perfusion-2), for the Company’s lead product candidate AI-700. Separately today the Company announced results for the RAMP-1 clinical trial and an intellectual property license with GE Healthcare. AI-700 is an investigational ultrasound contrast agent designed to assess myocardial perfusion, or blood flow to the heart muscle. Currently there is no approved ultrasound contrast agent to assess myocardial perfusion.
